Interesting coincidence that the major shareholder list was updated shortly after the final sales went through for the ex majors. Previous list dated 31/3.
Curious buys outweigh sells and did yesterday. Price is easily manipulated down on a known seller but has risen rapidly when sells dry up. This will not need any news to rise when seller has gone. Also odd that the 100k buyer yesterday consistently buying at 9p. Never happens when I buy. So what was that about.
Last podcast it was interesting JD inferred they had already had an approach did not say if it was for the whole or someone wanting a large piece which is when he said independence was important. No doubt will change once maturity is reached whenever that will be.
There was a further announcement on 25/7 of the joint venture between Yatai and Benchmark the purpose being; “to cultivate, manufacture, process, and market high content cannabidiol ("CBD") cannabis products; along with the R&D of medical cannabis; and the extraction, isolation, and purification of high-CBD cannabis oil for commercial applications.” Reading the NFX RNS re Ebers shows Ebers are responsible for “Nuformix will be responsible for early stage R&D activities and Ebers will be responsible for late-stage development, clinical programmes and commercialisation.” now NFX has already stated they have identified a product and are working on IP protection. So does that now put the responsibility on Ebers to perform the later stages. One can only assume Ebers ( a financially led co) will outsource that work. It seems too perfect a fit. Would Yatai set up a research facility without a starter project? https://www.bloomberg.com/press-releases/2019-07-25/benchmark-botanics-provides-update-on-investment-cooperation-agreement-with-zhejiang-yatai-pharmaceutical From the RNS Ebers not only medical based products but consumer therapeutic products that will be quick to market. Let’s hope patent approval is not too long.